AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03921164 — intervention group
Intervention type: PROCEDURE
Intervention: Trans-thoracic echocardiography
Description: Estimation of ventricular diastolic pressure by measuring mitral and aortic flow gradients by echocardiography (EPIQ G7 Philips© or similar) Determination of left ventricular volumes during the cardiac cycle by echocardiography (3D EPIQ G7 Philips© or similar).
Study NCT04819347 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albuvirtide
Description: Long-Acting HIV-1 Fusion Inhibitor (chemically modified peptide targeting HIV-1 gp41)
Study NCT04819347 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3BNC117
Description: Recombinant, fully human mAb of the IgG1κ isotype that specifically binds to HIV-1 gp120.
Study NCT03921164 — intervention group
Intervention type: PROCEDURE
Intervention: Applanation tonometry
Description: Measurements using the SphygmoCor radial tonometer (AtCor Medical, Pty Ltd, Sydney, Australia), the most widely used tonometer in clinical research for non-invasive central pressure measurement and pulse wave analysis. The central blood pressure is then estimated using a validated radial-aortic transfer function.~The tonometer requires prior calibration by mean (MAP) and diastolic (PAD) blood pressure measured with the conventional brachial cuff as validated in the literature.
Study NCT06168071 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: taVNS
Description: Recently, implantable VNS received FDA approval for augmenting motor recovery from ischemic stroke-induced hemiplegia when used during standard physical and occupational therapy sessions. VNS is FDA-approved for epilepsy therapy in children and is used for generalized refractory epilepsy. VNS may be achieved through an implantable stimulator on the left vagus nerve in the carotid sheath, or transcutaneously through the auricular branch of the vagus nerve (taVNS). All participants will be fitted with the device by attaching adhesive contacts to the left ear. Stimulation sessions will occur once for 30 minutes. The investigators will obtain baseline measure, tolerability questionnaires, vital signs, and EEG data.
Study NCT05306080 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tadekinig alfa (IL-18BP)
Description: Tadekinig alfa will be administered via subcutaneous injection. The site of subcutaneous injection should be rotated to avoid injection site reactions; e.g. the outside of the thighs, arms, and the various quadrants of the anterior abdominal wall.~* Injection #1/Day 1:~  o Loading dose of 4 mg/kg; Maximum dose of 350 mg.~* Repeat Injection(s): 2 mg/kg/injection; Maximum dose of 160 mg/injection. Missed doses will not be made up.~  * Injection #2/Day 3: Approximately 48 hours (+/- 5 hours) after receipt of the 1st injection.~ * Injection #3/Day 5: Approximately 48 hours (+/- 5 hours) after receipt of the 2nd injection.~ * Continued Dosing (Optional): Approximately q48-72 hours; If the subject is responsive to initial therapy, but has ongoing symptoms of CRS/CRHLS.
Study NCT05270694 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Public Health Intervention Package
Description: The intervention package consists of two components:~1. At the time of study enrollment, participants will attend an in-person training on how to properly take an at-home COVID-19 test. Study staff will verbally walk through the steps of the test with the participant while the participant administers the test on themselves, with the opportunity to ask questions and receive corrective feedback, as needed.~2. To make COVID-19 testing more accessible, participants will be provided five at-home COVID-19 testing kits at the training and then every other month throughout the course of the year-long study for a total of 35 kits.
Study NCT06480500 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine hydrochloride
Description: 55 patients will receive ketamine hydrochloride, over six infusions, flexibly dosed between 0.5 mg/kg to 0.85 mg/kg.
Study NCT06480500 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: i-CBT (Internet-based Cognitive Behavioural Therapy)
Description: Each week for 13 weeks, participants will watch an online module that last approximately 45-50 mins each, with homework at the end of each module. Homework is submitted and reviewed by a therapist, who will provide personalized feedback before progression to the next module.
Study NCT06480500 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: i-CBT (Internet-based Cognitive Behavioural Therapy)
Description: Each week for 13 weeks, participants will watch an online module that last approximately 45-50 mins each, with homework at the end of each module. Homework is submitted and reviewed by a therapist, who will provide personalized feedback before progression to the next module.
Study NCT06337630 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PLX038 + Tuvusertib
Description: Dose escalation will be conducted on the grid defined by the 4 doses of PLX038 (800 mg/m², 1000 mg/m², 1300 mg/m² and 1700 mg/m² IV every 21 days D1=D22) and 3 doses of Tuvusertib (90 mg, 130 mg and 180 mg QD for 10 days from D3, D3-12). Premedication with anti-emetic agents is not required prior to the initial infusion, but may be used for an individual patient, as needed.~All included patients will receive PLX038 + Tuvusertib until progression of disease, unacceptable toxicity, patient withdrawal of consent, investigator decision, lost to follow-up, death, patient non-compliance, or study termination by Sponsor.
Study NCT05774873 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI334 D
Description: Subjects will receive IBI334 D once a week during the first 28-day cycle (QW, 4 weeks), then biweekly (or other dose intervals recommended by the Investigator and Sponsor based on safety, toxicity and PK data), until disease progression, toxicity intolerance, withdrawal of consent, occurrence of other reasons for discontinuing study therapy, or treatment duration reaches 24 months, whichever occurs first.
Study NCT05774873 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI334 C
Description: Subjects will receive IBI334 C once a week during the first 28-day cycle (QW, 4 weeks), then biweekly (or other dose intervals recommended by the Investigator and Sponsor based on safety, toxicity and PK data), until disease progression, toxicity intolerance, withdrawal of consent, occurrence of other reasons for discontinuing study therapy, or treatment duration reaches 24 months, whichever occurs first.
Study NCT05774873 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI334 A
Description: Subjects will receive IBI334 A once a week during the first 28-day cycle (QW, 4 weeks), then biweekly (or other dose intervals recommended by the Investigator and Sponsor based on safety, toxicity and PK data), until disease progression, toxicity intolerance, withdrawal of consent, occurrence of other reasons for discontinuing study therapy, or treatment duration reaches 24 months, whichever occurs first.
Study NCT05774873 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI334 B
Description: Subjects will receive IBI334 B once a week during the first 28-day cycle (QW, 4 weeks), then biweekly (or other dose intervals recommended by the Investigator and Sponsor based on safety, toxicity and PK data), until disease progression, toxicity intolerance, withdrawal of consent, occurrence of other reasons for discontinuing study therapy, or treatment duration reaches 24 months, whichever occurs first.
Study NCT05774873 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI334 F
Description: Subjects will receive IBI334 F once a week during the first 28-day cycle (QW, 4 weeks), then biweekly (or other dose intervals recommended by the Investigator and Sponsor based on safety, toxicity and PK data), until disease progression, toxicity intolerance, withdrawal of consent, occurrence of other reasons for discontinuing study therapy, or treatment duration reaches 24 months, whichever occurs first.
Study NCT05774873 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI334 E
Description: Subjects will receive IBI334 C once a week during the first 28-day cycle (QW, 4 weeks), then biweekly (or other dose intervals recommended by the Investigator and Sponsor based on safety, toxicity and PK data), until disease progression, toxicity intolerance, withdrawal of consent, occurrence of other reasons for discontinuing study therapy, or treatment duration reaches 24 months, whichever occurs first.
Study NCT06480500 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam Hydrochloride
Description: 55 patients will receive midazolam hydrochloride, over six infusions, flexibly dosed between 0.02 mg/kg to 0.035 mg/kg.
Study NCT06282588 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darolutamide
Description: 2x300 mg tablets twice daily, for up to 96 weeks
Study NCT06282588 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Darolutamide matched placebo
Description: 2x300 mg tablets twice daily, for up to 96 weeks
Study NCT06282588 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Preferred regimens: 60 to 62 Gy delivered in 20 fractions of 3.0 to 3.1Gy per fraction; 36.25 Gy delivered in 5 fractions of 7.25 Gy per fraction, 2-3 fractions per week
Study NCT06282588 — intervention group
Intervention type: RADIATION
Group type: PLACEBO_COMPARATOR
Intervention: Radiotherapy
Description: Preferred regimens: 60 to 62 Gy delivered in 20 fractions of 3.0 to 3.1Gy per fraction; 36.25 Gy delivered in 5 fractions of 7.25 Gy per fraction, 2-3 fractions per week
Study NCT06282588 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Zoladex 3.6Mg Implant
Description: 3.6 mg, subcutaneous use
Study NCT06282588 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zoladex 3.6Mg Implant
Description: 3.6 mg, subcutaneous use
Study NCT06282588 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Zoladex LA
Description: 10.8 mg, subcutaneous use
Study NCT06282588 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zoladex LA
Description: 10.8 mg, subcutaneous use
Study NCT06282588 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Decapeptyl sustained release 22.5 mg
Description: 22.5 mg, intramusculair injection
Study NCT06282588 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decapeptyl sustained release 22.5 mg
Description: 22.5 mg, intramusculair injection
Study NCT06282588 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Decapeptyl sustained release 11.25 mg
Description: 11.25 mg, intramusculair injection
Study NCT06282588 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decapeptyl sustained release 11.25 mg
Description: 11.25 mg, intramusculair injection
Study NCT06282588 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Depo-Eligard 45 mg
Description: 45 mg, subcutaneous use
Study NCT06282588 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Depo-Eligard 45 mg
Description: 45 mg, subcutaneous use
Study NCT06282588 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Depo-Eligard 22.5 mg
Description: 22.5 mg, subcutaneous use
Study NCT06282588 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Depo-Eligard 22.5 mg
Description: 22.5 mg, subcutaneous use
Study NCT06282588 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Depo-Eligard 7.5 mg
Description: 7.5 mg, subcutaneous use
Study NCT06282588 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Depo-Eligard 7.5 mg
Description: 7.5 mg, subcutaneous use
Study NCT06282588 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Firmagon 120 MG Injection
Description: 120 mg, subcutaneous use
Study NCT06282588 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Firmagon 120 MG Injection
Description: 120 mg, subcutaneous use
Study NCT06282588 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Firmagon 80 MG Injection
Description: 80 mg, subcutaneous use
Study NCT06282588 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Firmagon 80 MG Injection
Description: 80 mg, subcutaneous use
Study NCT06282588 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Docetaxel
Description: 75 mg per square m, IV infusion
Study NCT06282588 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: 75 mg per square m, IV infusion
Study NCT04390113 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Posoleucel (ALVR105)
Description: Administered as 2-4 milliliter infusion, visually identical to placebo
Study NCT04390113 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered as 2-4 milliliter infusion, visually identical to Posoleucel (ALVR105)
Study NCT04886583 — intervention group
Intervention type: DEVICE
Intervention: Gabi Baby Band
Description: Every enrolled patient must wear the Gaby Baby Band on the left arm in the aim to perform data analytics after the test has been performed
Study NCT06134739 — intervention group
Intervention type: OTHER
Intervention: No intervention.
Description: Observational study, no intervention.
Study NCT04495387 — intervention group
Intervention type: DRUG
Intervention: Chemotherapy
Description: standard adjuvat chemotherapy for reast and colo cancer
Study NCT04698980 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: blood samples (venous and capillary at the fingertip)
Description: For each participant, the intervention will be a fingertip sample to perform the STANDARD G6PD test and two blood samples on EDTA to perform the reference test
Study NCT04993326 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: emPOWERed To Change Program
Description: Online Diabetes Self-Management Education and Support along with COVID-19 prevention and protection (vaccination) education and resource information
Study NCT04246970 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Prehabilitation
Description: Supervised training program of 8-weeks and a frequency of 2 days/week. It includes interval aerobic exercise (5 cycles of 2 minutes at 70 percentage of Watts or heart rate of cardiopulmonary exercise testing (CEPT) and 3 minutes of active rest at 40 percentage; peripheral muscle training and balance exercises in a circuit of 10 phases, 10 to 15 repetitions, from 1 to 3 sets (the participants will work at moderate intensity, no more than 5-6/10 on the modified Borg scale); Inspiratory Muscle Training (IMT) through a threshold loading device \[2 sessions / day, 3 sets of 15 repetitions, at 60-70 percentage of the maximum inspiratory pressure (cmH2O)\]; ventilatory reeducation by an incentive inspirator based on the vital capacity evaluated in the initial spirometry. Both the aerobic modality and the resistance training, will increase the intensity of work (HR, Watts, Kg or cmH2O) between 2-5 percentage every 2 weeks complying with the principle of training overload.
Study NCT04246970 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Prehabilitation and posttransplant training program
Description: Prehabilitation will be followed by a posttransplant training program. In this, the patient will perform supervised exercise (IIa interval aerobic exercise and resistance training) 2 days / week, and a physical exercise program at home until completing a total of 5 sessions / week in the aerobic modality. In the unsupervised phase (IIb), the patient will continue with the learned physical exercise program, but without supervision, 5 sessions / week (including a minimum of 2 non-consecutive sessions to perform resistance training).
Study NCT06526858 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HyperQureTM Renal Denervation (RDN) System:
Description: The HyperQure RDN System consists of a Generator that generates RF energy and a Laparoscopic Instrument that delivers the RF energy generated by the generator to the treatment area. Through a extravascular(laparoscopic) approach, the renal artery is accessed through the retroperitoneum, which is the closest path to the renal artery. After wrapping 360 degrees of renal artery, RDN is performed as per the preset parameters of 50 degrees and 70 seconds.~The target blood vessels will be planned by CTA before the procedure, and the proximal and distal areas of the right and left main renal artery are treated once at a distance of at least 3 mm respectively, and RDN will be also performed on the branch or accessory vessels confirmed to be suitable for the procedure by CTA.
Study NCT05655793 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Tear Fluid collection (Schirmer's strip)
Description: Tear fluid will be collected non-invasively form all participants with the use of Schirmer's strips, which is a small paper strip placed in the lower eye lid for a maximum of 5 minutes.
Study NCT05655793 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Retinal imaging
Description: The retina from all participants will be visualised with the use of a standard (Clarus 700 Zeiss), ultra-wide field (Optos), and cross-sectional (Optical Coherence Tomography) retinal images.
Study NCT06528223 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: biopsy or operation
Description: To obtain a biopsy pathology or surgical pathology according to the clinical process of PDAC.
Study NCT05188846 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SDF
Description: 1. Group 1: cleaning the occlusal surface to be treated with toothbrush. Decayed tissue from the affected teeth will not be removed for the SDF group.~Clinical procedure for SDF application: it will apply according to the SDF manufacturer Instructions as follows:(1) the surrounding gingival tissues and lips will be protected with petroleum jelly to avoid staining and irritation,(2) the affected tooth will be isolated and keep dry with cotton rolls and saliva ejectors, (3) one drop of SDF (SDI RIVA STAR ), will be placed into a disposable dish, (4) SDF will be applied with a micro-sponge directly to the affected tooth surface(s), (5) allowed to soak in for 2 min, then air-dried. Then will be followed by the Potassium iodide (KI) liquid to decrease discoloration caused by SDF. The KI liquid will be reapplied until no more white perception observed to form.
Study NCT05188846 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: SDF + ART (SMART technique )
Description: 2. Group 2: SDF+ART clinical procedure: (1)cleaning the occlusal surface to be treated with toothbrush.,(2) carious dentin will be removed using a small excavator (Spoon excavator ),(3) the cavity will be cleaned and dried, (4)cavity walls and floor will be conditioned for 10s, then washed and dried, (5) SDF will be applied as mentioned above followed by cavity restoration using resin-reinforced glass ionomer restorative material (SDI RIVA ).
Study NCT02202473 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lamivudine
Study NCT02202473 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lamivudine+Oxymatrine Capsules
Study NCT06255899 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Education Program on Injury Prevention
Description: The didactic component of the injury prevention education program includes information on prevalence of injuries in female athletes, biomechanical risk factors for injury, and effectiveness of injury prevention programs (IPP) for mitigation of injury risk. Examples of different activities from the IPP, including proper and improper movement strategies will be provided. Athletes will be instructed as a group on how to properly perform of each activity of the IPP, and will be given an opportunity to practice. Athletes, coaches, and staff will be provided with links to written instructions and videos of proper performance for each activity. The IPP will be performed at least 3 times/week prior to practice. Coaches, staff, and athletes will be encouraged to provide supervision and feedback on performance of the IPP throughout the season.
Study NCT06255899 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education Program on Injury Prevention
Description: The didactic component of the injury prevention education program includes information on prevalence of injuries in female athletes, biomechanical risk factors for injury, and effectiveness of injury prevention programs (IPP) for mitigation of injury risk. Examples of different activities from the IPP, including proper and improper movement strategies will be provided. Athletes will be instructed as a group on how to properly perform of each activity of the IPP, and will be given an opportunity to practice. Athletes, coaches, and staff will be provided with links to written instructions and videos of proper performance for each activity. The IPP will be performed at least 3 times/week prior to practice. Coaches, staff, and athletes will be encouraged to provide supervision and feedback on performance of the IPP throughout the season.
Study NCT06255899 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Individualized Feedback + Education Program on Injury Prevention
Description: In addition to the education program, participants in this group will receive individualized feedback on performance of the IPP. The participant will be videotaped while performing the IPP, and movement errors and compensations will be identified to provide a basis for feedback sessions to correct movement. The session will include different forms of feedback including showing the athlete their video, identifying the error or compensation, and providing verbal, tactile, and visual feedback to correct the error or compensation. Common errors and compensations, along with verbal cues and corrections, have been identified and manualized for the study. Two additional feedback sessions will be scheduled at regular intervals during the season to provide feedback on performance throughout the season. Participants in this group will be encouraged to provide peer feedback to one another.
Study NCT05531396 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Agility Training
Description: Participants will receive 60 minutes of exercise, twice a week, for a total of 8 weeks, and training will be conducted by a well-trained physical therapist. The intervention will comprise a 5-minute warm-up, 45 minutes of main exercise, and a 10-minute cool-down period, for a total of 60 minutes each session. During the warm-up and cool-down, participants will do static and dynamic whole-body stretching exercises.